366 related articles for article (PubMed ID: 25108079)
1. Synthesis and biological evaluation of novel thieno[2,3-d]pyrimidine-based FLT3 inhibitors as anti-leukemic agents.
Yang JS; Park CH; Lee C; Kim H; Oh C; Choi Y; Kang JS; Yun J; Jeong JH; Kim MH; Han G
Eur J Med Chem; 2014 Oct; 85():399-407. PubMed ID: 25108079
[TBL] [Abstract][Full Text] [Related]
2. Structural modifications at the 6-position of thieno[2,3-d]pyrimidines and their effects on potency at FLT3 for treatment of acute myeloid leukemia.
Kim H; Lee C; Yang JS; Choi S; Park CH; Kang JS; Oh SJ; Yun J; Kim MH; Han G
Eur J Med Chem; 2016 Sep; 120():74-85. PubMed ID: 27187860
[TBL] [Abstract][Full Text] [Related]
3. Synthetic strategy for increasing solubility of potential FLT3 inhibitor thieno[2,3-d]pyrimidine derivatives through structural modifications at the C
Oh C; Kim H; Kang JS; Yun J; Sim J; Kim HM; Han G
Bioorg Med Chem Lett; 2017 Feb; 27(3):496-500. PubMed ID: 28043794
[TBL] [Abstract][Full Text] [Related]
4. Discovery and development of extreme selective inhibitors of the ITD and D835Y mutant FLT3 kinases.
Baska F; Sipos A; Őrfi Z; Nemes Z; Dobos J; Szántai-Kis C; Szabó E; Szénási G; Dézsi L; Hamar P; Cserepes MT; Tóvári J; Garamvölgyi R; Krekó M; Őrfi L
Eur J Med Chem; 2019 Dec; 184():111710. PubMed ID: 31614258
[TBL] [Abstract][Full Text] [Related]
5. Structure-activity relationship studies of pyrazolo[3,4-d]pyrimidine derivatives leading to the discovery of a novel multikinase inhibitor that potently inhibits FLT3 and VEGFR2 and evaluation of its activity against acute myeloid leukemia in vitro and in vivo.
Yang LL; Li GB; Ma S; Zou C; Zhou S; Sun QZ; Cheng C; Chen X; Wang LJ; Feng S; Li LL; Yang SY
J Med Chem; 2013 Feb; 56(4):1641-55. PubMed ID: 23362959
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel 4-azaaryl-N-phenylpyrimidin-2-amine derivatives as potent and selective FLT3 inhibitors for acute myeloid leukaemia with FLT3 mutations.
Long Y; Yu M; Ochnik AM; Karanjia JD; Basnet SK; Kebede AA; Kou L; Wang S
Eur J Med Chem; 2021 Mar; 213():113215. PubMed ID: 33516985
[TBL] [Abstract][Full Text] [Related]
7. Novel acylureidoindolin-2-one derivatives as dual Aurora B/FLT3 inhibitors for the treatment of acute myeloid leukemia.
Jagtap AD; Chang PT; Liu JR; Wang HC; Kondekar NB; Shen LJ; Tseng HW; Chen GS; Chern JW
Eur J Med Chem; 2014 Oct; 85():268-88. PubMed ID: 25089810
[TBL] [Abstract][Full Text] [Related]
8. Dual Inhibition of Mnk2 and FLT3 for potential treatment of acute myeloid leukaemia.
Diab S; Abdelaziz AM; Li P; Teo T; Basnet SKC; Noll B; Rahaman MH; Lu J; Hou J; Yu M; Le BT; Albrecht H; Milne RW; Wang S
Eur J Med Chem; 2017 Oct; 139():762-772. PubMed ID: 28863357
[TBL] [Abstract][Full Text] [Related]
9. Discovery of quinolinone derivatives as potent FLT3 inhibitors.
Chung HJ; Kamli MR; Lee HJ; Ha JD; Cho SY; Lee J; Kong JY; Han SY
Biochem Biophys Res Commun; 2014 Mar; 445(3):561-5. PubMed ID: 24530392
[TBL] [Abstract][Full Text] [Related]
10. A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with
Yamaura T; Nakatani T; Uda K; Ogura H; Shin W; Kurokawa N; Saito K; Fujikawa N; Date T; Takasaki M; Terada D; Hirai A; Akashi A; Chen F; Adachi Y; Ishikawa Y; Hayakawa F; Hagiwara S; Naoe T; Kiyoi H
Blood; 2018 Jan; 131(4):426-438. PubMed ID: 29187377
[TBL] [Abstract][Full Text] [Related]
11. Amino alkynylisoquinoline and alkynylnaphthyridine compounds potently inhibit acute myeloid leukemia proliferation in mice.
Naganna N; Opoku-Temeng C; Choi EY; Larocque E; Chang ET; Carter-Cooper BA; Wang M; Torregrosa-Allen SE; Elzey BD; Lapidus RG; Sintim HO
EBioMedicine; 2019 Feb; 40():231-239. PubMed ID: 30686755
[TBL] [Abstract][Full Text] [Related]
12. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
[TBL] [Abstract][Full Text] [Related]
13. Discovery of (R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia.
Li X; Wang A; Yu K; Qi Z; Chen C; Wang W; Hu C; Wu H; Wu J; Zhao Z; Liu J; Zou F; Wang L; Wang B; Wang W; Zhang S; Liu J; Liu Q
J Med Chem; 2015 Dec; 58(24):9625-38. PubMed ID: 26630553
[TBL] [Abstract][Full Text] [Related]
14. A series of novel aryl-methanone derivatives as inhibitors of FMS-like tyrosine kinase 3 (FLT3) in FLT3-ITD-positive acute myeloid leukemia.
Sellmer A; Pilsl B; Beyer M; Pongratz H; Wirth L; Elz S; Dove S; Henninger SJ; Spiekermann K; Polzer H; Klaeger S; Kuster B; Böhmer FD; Fiebig HH; Krämer OH; Mahboobi S
Eur J Med Chem; 2020 May; 193():112232. PubMed ID: 32199135
[TBL] [Abstract][Full Text] [Related]
15. Discovery and structure - activity relationship exploration of pyrazolo[1,5-a]pyrimidine derivatives as potent FLT3-ITD inhibitors.
Chen Y; Bai G; Li Y; Ning Y; Cao S; Zhou J; Ding J; Zhang H; Xie H; Duan W
Bioorg Med Chem; 2021 Oct; 48():116422. PubMed ID: 34583130
[TBL] [Abstract][Full Text] [Related]
16. Identification of Pyrrolo[2,3- d]pyrimidine-Based Derivatives as Potent and Orally Effective Fms-like Tyrosine Receptor Kinase 3 (FLT3) Inhibitors for Treating Acute Myelogenous Leukemia.
Yuan X; Chen Y; Zhang W; He J; Lei L; Tang M; Liu J; Li M; Dou C; Yang T; Yang L; Yang S; Wei Y; Peng A; Niu T; Xiang M; Ye H; Chen L
J Med Chem; 2019 Apr; 62(8):4158-4173. PubMed ID: 30939008
[TBL] [Abstract][Full Text] [Related]
17. Identification of pyrrolo[2,3-d]pyrimidines as potent HCK and FLT3-ITD dual inhibitors.
Koda Y; Kikuzato K; Mikuni J; Tanaka A; Yuki H; Honma T; Tomabechi Y; Kukimoto-Niino M; Shirouzu M; Shirai F; Koyama H
Bioorg Med Chem Lett; 2017 Nov; 27(22):4994-4998. PubMed ID: 29037944
[TBL] [Abstract][Full Text] [Related]
18. Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor.
Zhang L; Lakkaniga NR; Bharate JB; Mcconnell N; Wang X; Kharbanda A; Leung YK; Frett B; Shah NP; Li HY
Eur J Med Chem; 2021 Dec; 225():113776. PubMed ID: 34479037
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of indolin-2-one-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase3 (FLT3).
Ma F; Liu P; Lei M; Liu J; Wang H; Zhao S; Hu L
Eur J Med Chem; 2017 Feb; 127():72-86. PubMed ID: 28038328
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a benzimidazole-based dual FLT3/TrKA inhibitor targeting acute myeloid leukemia.
Dokla EME; Abdel-Aziz AK; Milik SN; McPhillie MJ; Minucci S; Abouzid KAM
Bioorg Med Chem; 2022 Feb; 56():116596. PubMed ID: 35033885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
